LY96 and nephritis: In recent years, MD‐2 inhibition by pharmacological and genetic methods has been found to attenuate inflammatory diseases, such as sepsis 25, lung inflammation 26, kidney inflammation 27, asthma 28, nonalcoholic steatohepatitis and fibrosis 29.